Nanostar Sieving®, the next generation of polymer synthesis in liquid phase
Where liquid phase polymer synthesis and our advanced membranes meet, to enable superior manufacturing of advanced therapeutics.
Nanostar Sieving® Process Video · 1:02
The Nanostar Sieving® platform is built on Organic Solvent Nanofiltration separation, using our proprietary Exact-10™ membranes. It allows synthesis of exact polymer pharmaceuticals fully in liquid phase, using a single solvent mixture, without precipitation or extraction steps.
A first monomer is attached to a central hub molecule, creating a “nanostar” with enhanced molecular size.
Further monomers are added iteratively, with the growing polymer purified at every step via purpose-designed nanomembrane filtration.
Separation happens purely by molecular size, so the platform is chemistry-agnostic and slots into our semi-automated Nanostar Synthesiser.
The Bottleneck in Oligonucleotide Therapeutics Manufacturing
Oligonucleotide drugs for diseases with large patient populations, such as cardiovascular diseases, Alzheimer’s and Hepatitis B, are now progressing through clinical trials. However, once approved, these drugs are at risk of being inaccessible to patients due to high costs and limited manufacturing capacity.
Read the full context
The success of oligonucleotide therapeutics has been largely attributed to their ability to treat rare diseases, particularly those caused by genetic mutations. In recent years, their pharmaceutical applications have expanded to show potential in treating prevalent diseases. Several oligonucleotide-based drugs targeting diseases with large patient populations, such as cardiovascular diseases, Alzheimer’s and Hepatitis B, are now progressing through clinical trials, on their way to revolutionising treatments for affected patients.
However, once approved, these drugs are at risk of being inaccessible to patients due to high costs and limited manufacturing capacity.
Existing techniques such as solid phase oligonucleotide synthesis work efficiently at smaller scales, making them ideal for rare disease therapeutics. As more genetic targets are identified for prevalent diseases, the industry requires novel, scalable and efficient manufacturing solutions to ensure the viability and accessibility of these upcoming blockbuster drugs.
This is exactly the gap Nanostar Sieving® was built to close.
See the advantages →The Advantage of the Nanostar Sieving® Platform for Oligonucleotide Synthesis
What are oligonucleotides?
Nucleotides are monomeric building blocks of nucleic acids like DNA and RNA. They each contain a nitrogenous base, a pentose sugar and a phosphate and can be linked together to form a polymer chain.
Oligonucleotides, also referred to as oligos, are a short polymeric chain of 13-25 nucleotides. These oligonucleotides occur naturally but are typically synthesised for research and therapeutic applications. Due to their ability to bind to complementary nucleic acid bases, oligos are often used as primers for DNA amplification and as tools to treat diseases by modulating gene expression.
How an oligonucleotide drug works
Many oligonucleotide therapeutics work by binding directly to the messenger RNA (mRNA) that would otherwise be translated into a disease-causing protein, stopping the harmful protein from ever being expressed.
Disease-causing mRNA
A faulty or overactive gene produces mRNA that codes for a harmful protein.Oligo binds by base pairing
The therapeutic oligo matches and binds the target mRNA sequence exactly.Protein is never made
Bound mRNA is degraded or blocked from translation, silencing the gene.Shared mechanism for ASOs, siRNA and miRNA. saRNA works in reverse — increasing rather than silencing expression.
Types of Oligonucleotides
ASO
Single-stranded · 15–25 ntAlters mRNA expression, preventing disease-causing proteins, degrading mRNA, or modifying splicing.
Read more
ASOs target and alter mRNA expression precisely, by preventing disease-causing proteins, degrading mRNA, or modifying RNA splicing.
siRNA
Double-stranded · 20–25 bpSilences genes through RNA interference (RNAi), degrading complementary mRNA.
Read more
siRNA is a double stranded, non-coding short RNA molecule, typically 20–25 base pairs, regulating gene expression through RNAi.
miRNA
Single-strandedRepresses translation by binding target mRNA, regulating gene expression.
Read more
miRNA is a single stranded, non-coding short RNA molecule with a gene silencing mechanism via translational repression.
saRNA
Double-stranded · the exceptionIncreases rather than silences gene expression, by binding gene promoters.
Read more
saRNA is double stranded and non-coding, regulating gene expression by binding promoters to stimulate transcription, increasing rather than silencing genes.
Where are you in your program?
Pick the path closest to you, and we'll take it from there.
